Mahdi Babaei

Mr. Mahdi Babaei

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 February 2026 in Biomedicines
Verified
Journal Article
Open access
PDF file
SSSepideh Hajipour Sardouie
Sepideh Hajipour Sardouie
Mahdi BabaeiMahdi Babaei
Mahdi Babaei
Mahsa NaseriMahsa Naseri
Mahsa Naseri
SMShervin Mehrtash
Shervin Mehrtash
MFMohammadhossein Faramarzi
Mohammadhossein Faramarzi
MMMartin James McKeown
Martin James McKeown
Background/Objectives: Parkinson’s disease (PD) is associated with alterations in resting-state Electroencephalogram (EEG) biomarkers. Identifying stimulation protocols that reliably shift these biomarkers toward healthy-like patterns is essential for developing personalized neuromodulation strategies. This study introduces a rapid, biomarker-driven framework for screening the EEG effects of diverse Galvanic Vestibular Stimulation (GVS) waveforms in PD. Methods: More than 300 subthreshold GVS stimuli were delivered during resting-state EEG to PD (n = 5) subjects and Healthy Controls (n = 5). A composite biomarker score that included spectral, cross-frequency, aperiodic, and complexity measures quantified stimulation-related changes. A linear classifier and multi-criteria decision analysis were used to evaluate and rank stimuli. Results: Stimulation produced consistent improvements in the composite biomarker score, with the strongest effects observed for beta-range sinusoids, multisine waveforms, frequency-modulated stimuli with a 75 Hz carrier, and PAC-modulated signals. No significant post-stimulation carryover effects were detected. Conclusions: While preliminary, this exploratory framework enables rapid, interpretable profiling of EEG responses to non-invasive stimulation in PD. By prioritizing candidate GVS protocols based on biomarker shifts rather than behavioural endpoints, the approach provides a practical foundation for future personalized neuromodulation strategies.

5 November 2026 in Journal of Neural Engineering
Verified
Journal Article
Open access
SSSepideh Hajipour Sardouie
Sepideh Hajipour Sardouie
MNMahsa Naseri
Mahsa Naseri
Mahdi BabaeiMahdi Babaei
Mahdi Babaei
ZKZahra Kavian
Zahra Kavian
SMShervin Mehrtash
Shervin Mehrtash
MMMartin James McKeown
Martin James McKeown
Electroencephalography (EEG) provides a high-temporal-resolution, noninvasive window into some of the abnormalities underlying Parkinson’s disease (PD), yet reported electrophysiological biomarkers vary widely across studies due to differences in preprocessing, feature extraction, and analytical pipelines. Here we provide the first comprehensive, multi-dataset benchmarking of 16 EEG-derived biomarkers, including phase-amplitude coupling, beta burst metrics, aperiodic components, complexity measures, and beta waveform features, to evaluate their robustness, reliability, and clinical discriminability. Using three independent resting-state EEG datasets, with two preprocessing conditions evaluated for one dataset, we assessed the effects of preprocessing, window length, within-session variability, channel aggregation strategies, and clinical group differences (healthy controls vs. PD OFF-medication, healthy controls vs. PD ON-medication, and PD OFF- vs. ON-medication). Cross-dataset reproducibility of group-level effects was additionally evaluated using effect-size pattern similarity, biomarker rank concordance, effect-direction consistency, and random-effects meta-analysis. Aperiodic features, entropy and complexity measures, and fractal metrics demonstrated high methodological robustness across preprocessing methods, window lengths, and aggregation strategies, and several showed disease- and medication-related effects across datasets, although effect magnitude and statistical significance varied across datasets and analytical conditions. In contrast, oscillatory biomarkers, including beta-gamma phase-amplitude coupling, burst-derived metrics, and waveform-asymmetry features, showed substantial variability across methodological choices and lower within-session consistency. However, this methodological sensitivity should not necessarily be interpreted as lower biological relevance, as these measures may capture more transient or state-dependent physiological dynamics. Fully-denoised data improved group-level separability, for several biomarkers in Dataset 1. Together, these findings identify several biomarkers with comparatively strong methodological robustness for further biological and clinical validation and highlight methodological factors that contribute to inconsistencies in the PD literature. This benchmarking framework provides practical guidance for standardizing biomarker analysis while emphasizing that methodological robustness, biological sensitivity, and clinical utility represent distinct dimensions of biomarker performance.